NCT00867568 2024-08-06
TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Milton S. Hershey Medical Center
Phase 1 Completed
Clinical Trials
9 trialsNCT01483820 2024-08-06
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT01505608 2024-08-06
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma
Milton S. Hershey Medical Center
Phase 1/2 Terminated
NCT02187822 2021-02-04
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Terminated
NCT01582152 2019-06-05
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01332630 2018-09-20
TPI 287 in Breast Cancer Metastatic to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01067066 2017-07-21
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01113463 2016-10-31
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01340729 2013-04-05
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn